Read more about Prime’s leading research and insights Real-World 2-Year Clinical Outcomes Following Initiation of Glucagon-Like Peptide-1 Agonists to Treat Obesity Without Diabetes Among a...

Pipeline (late-stage development) Name Manufacturer Route of administration Mechanism of action Proposed / studied indication Status Durvalumab (Imfinzi) AstraZeneca; MedImmune IV Programmed...

Jan. 28, 2025 – hydrochlorothiazide (Inzirqo) 505(b)(2) NDA approval; Standard Review; first oral suspension formulation of hydrochlorothiazide; previously available oral solutions are no longer...

May 1, 2024 Obesity is a global epidemic and major public health issue that has grown in prevalence over recent decades in adults, adolescents and children. This Clinical Insights white paper...

PUBLICATIONS FDA Decisions Expected: February 2025 Drug pipeline for February 2025 Your monthly synopsis of new drugs expected to hit the market At Prime Therapeutics (Prime), we have positioned...

January 31, 2025 All brand names are property of their respective owners. Dec. 13, 2024 – cosibelimab-ipdl (Unloxcyt) Checkpoint’s Unloxcyt has received FDA approval for the treatment of adults...

Proposed indications Non-muscle invasive bladder cancer (NMIBC) FDA approval timeline March to May 2026 Standard Review Place in therapy Sasanlimab is a humanized immunoglobulin G4 (IgG4)...

publications High-Cost Therapy Profile: April 2025 Deramiocel Intravenous (IV) | Nippon Shinyaku Co., Ltd./Capricor Therapeutics, Inc. Clinical deep dive Disease state overview DMD is a severe,...